• Suche
1 Aktie gratis
Trading
Suche
1 Aktie gratis
Wertpapierhandel für 0 Euro
Trading
zero-Trading
ETF-Sparplan

Altai Resources Aktie

0,0450EUR
±0,0000EUR
±0,00%
17:47:17
FSE
0,0700CAD
+0,0100CAD
+16,67%
20.05.2022
CDNX

WKN: 893520 / ISIN: CA02136K1084 / Symbol: ARSEF

  Kaufen  
Verkaufen
oder
mehr Daten anzeigen
Werbung

Times and Sales (XETRA)

ZeitKursUmsatz
Zur Zeit stehen keine Daten zur Verfügung
weiter
Werbung

News zu Altai Resources Inc

n/a

Analysen zu Altai Resources Inc

n/a

Aktuelle News zu

23:29 UhrRutschen die US-Börsen in einen langanhaltenden Bärenmarkt?
23:28 UhrSummit Midstream Partners, LP Announces Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
23:27 Uhr100% AND MLB ALL-STAR FERNANDO TATIS, JR. DEBUT 2022 LIMITED-EDITION SPORT PERFORMANCE EYEWEAR COLLECTION
23:25 UhrNew 'rebel' elopement planner kicks tradition to the curb with all-inclusive service for alternative couples
23:23 UhrUSA weisen Russlands Forderung nach Aufhebung von Sanktionen zurück
23:23 UhrCarisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting
23:16 UhrBGL Announces the Sale of ROCA ACERO S.A. de C.V.
23:16 UhrDouglas Emmett Declares Quarterly Cash Dividend
23:15 UhrVenzee Technologies Updates Schedule Details for Webcast and First Quarter 2022 Financial Release
23:15 UhrCaris Life Sciences to Showcase Extensive Research with Leading Cancer Centers Reflecting Its Commitment to Improving Outcomes for Patients at ASCO 2022
23:15 UhrVenzee Technologies Updates Schedule Details for Webcast and First Quarter 2022 Financial Release
23:12 UhrNASDAQ, S&P 500 & Co: Tesla-Aktie, Apple-Aktie, Amazon-Aktie, Microsoft-Aktie & Co im Fokus: Das sind die Bilanzen der Tech-Riesen in der aktuellen Saison
23:10 UhrProtagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
23:10 UhrFür Tesla: Musk sucht auf Twitter nach neuer Rechtsabteilung - und erntet Kritik
23:08 UhrKaryopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
23:07 UhrNASA Supports Small Business Research to Power Future Exploration
23:05 UhrSILVERCORP REPORTS ADJUSTED EARNINGS OF $52.4 MILLION, $0.30 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $107.4 MILLION FOR FISCAL 2022
23:05 UhrNew Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access
23:05 UhrElevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022
23:05 UhrSILVERCORP REPORTS ADJUSTED EARNINGS OF $52.4 MILLION, $0.30 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $107.4 MILLION FOR FISCAL 2022
23:05 UhrPuma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
23:01 UhrElectra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery
23:01 UhrFDA Flexibilities, Collaboration to Yield Millions of Bottles of Specialized Medical Infant Formula in Coming Months to Increase U.S. Supply
23:01 UhrMILE MARKER INDUSTRIES ANNOUNCES MANAGEMENT CHANGES
23:01 UhrI-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
23:01 UhrGracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting
23:01 UhrElectra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery
23:01 UhrXencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
23:01 UhrSpectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
23:00 UhrSQI Diagnostics Reports Second Quarter 2022 Results
23:00 UhrTriNet to Participate at the Stifel 2022 Cross Sector Insight Conference
23:00 UhrCTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual Meeting
23:00 UhrNext-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers
23:00 UhrMARTIN UNIVERSITY ANNOUNCES DATA SECURITY INCIDENT
23:00 UhrLeap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting
23:00 UhrBelong.Life Real-World Patient Research Analyzes the Impact of COVID-19 on Cancer Diagnosis in ASCO 2022 Abstract
23:00 UhrZovio Advances Turnaround Plan and Strengthens Financial Position
23:00 UhrNEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022
23:00 UhrInvestigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
23:00 UhrLilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
23:00 UhrSQI Diagnostics Reports Second Quarter 2022 Results
23:00 UhrLANESBOROUGH REIT REPORTS 2022 FIRST QUARTER RESULTS
23:00 UhrForan Announces Voting Results from 2022 AGSM
23:00 UhrMinto Apartment REIT Reports Voting Results from Annual General Meeting of Unitholders
23:00 UhrLinamar Corporation Announces Voting Results from Annual General Meeting
23:00 UhrIpsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
23:00 UhrMerus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
22:57 UhrDenali Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing May 31, 2022.
22:54 UhrThe Doctors Company Names Megan Mahoney, MD, MBA, to Board of Governors
22:51 UhrQUESTEX ANNOUNCES SECURITYHOLDER APPROVAL OF PLAN OF ARRANGEMENT
finanzen.net zero

Aktien kaufen ohne Kosten

finanzen.net zero
Aktien, ETFs, Derivate, Kryptos und mehr jetzt für 0 Euro pro Trade handeln!
JETZT INFORMIEREN
Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
JETZT MEHR ERFAHREN
Zur klassischen Ansicht wechseln
Hilfe & Kontakt
Impressum
Werben
Presse
mehr anzeigen